Continuous flow peptide synthesis is revolutionizing peptide API production, offering advantages in safety, efficiency, and scalability compared to traditional batch processes. The technology is being adopted by leading CDMOs to enhance manufacturing capabilities and meet growing demand.
Continuous flow synthesis integrates reaction, separation, concentration, and crystallization into a single uninterrupted process with real-time in-line monitoring[reference:139]. This approach enables precise, scalable, and efficient manufacturing with reduced solvent usage and waste. Continuous flow also offers safety advantages for reactions involving hazardous reagents.
Recent developments in continuous flow peptide synthesis include the Peptide-Builder from Vapourtec Ltd, a compact benchtop peptide synthesizer incorporating Variable Bed Flow Reactor technology[reference:140]. This system enables continuous-flow solid-phase peptide synthesis with precise control of reaction conditions and support for high-throughput synthesis of multiple peptide sequences[reference:141].
Industry adoption of continuous flow technology is accelerating. SynCrest Inc. launched its GMP-compliant Naruto Plant equipped with a continuous flow synthesis platform for peptide and nucleotide API production in May 2023[reference:142]. The platform allows rapid manufacturing of over 100 types of non-natural amino acids and high-purity special amidites[reference:143].
Benefits of continuous flow peptide synthesis include reduced lead times, lower production costs, improved quality consistency, and enhanced safety. The technology also supports more sustainable manufacturing with reduced solvent usage and waste. At PeptideHub, we are investing in continuous flow technology to enhance our manufacturing capabilities and provide cost-competitive peptide APIs for our customers.